Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years
Public ClinicalTrials.gov record NCT00346073. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study to Evaluate Immunogenicity and Safety of Boostrix Compared to Adacel When Administered as a Booster Vaccination in Adults Aged 19 to 64 Years of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
GSK Biologicals' dTpa vaccine has recently been approved by the US Food and Drug Administration (FDA) for booster vaccination of adolescents aged 10 to 18 years. The ACIP has recently issued provisional recommendations for universal adult Tdap vaccination. The current study will provide pivotal data in support of extending the age range for Boostrix vaccine to include adults 19-64 years of age.
Study identification
- NCT ID
- NCT00346073
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,337 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 19 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 13, 2006 (Actual)
- Primary completion
- Mar 1, 2007 (Actual)
- Completion
- Mar 7, 2007 (Actual)
- Last update posted
- Aug 7, 2018
2006 – 2007
United States locations
- U.S. sites
- 42
- U.S. states
- 24
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Huntsville | Alabama | 35802 | — |
| GSK Investigational Site | Chandler | Arizona | 85224 | — |
| GSK Investigational Site | Mesa | Arizona | 85203 | — |
| GSK Investigational Site | Mesa | Arizona | 85213 | — |
| GSK Investigational Site | Peoria | Arizona | 85381 - 4828 | — |
| GSK Investigational Site | Phoenix | Arizona | 85014 | — |
| GSK Investigational Site | Tempe | Arizona | 85283 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72205 | — |
| GSK Investigational Site | San Diego | California | 92103-6204 | — |
| GSK Investigational Site | San Diego | California | 92108 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80909 | — |
| GSK Investigational Site | Pueblo | Colorado | 81001 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20036 | — |
| GSK Investigational Site | Melbourne | Florida | 32901 | — |
| GSK Investigational Site | Miami | Florida | 33143 | — |
| GSK Investigational Site | Pembroke Pines | Florida | 33024 | — |
| GSK Investigational Site | Tampa | Florida | 33603 | — |
| GSK Investigational Site | Boise | Idaho | 83713 | — |
| GSK Investigational Site | Peoria | Illinois | 61602 | — |
| GSK Investigational Site | South Bend | Indiana | 46601 | — |
| GSK Investigational Site | Bardstown | Kentucky | 40004 | — |
| GSK Investigational Site | Richland | Michigan | 49083 | — |
| GSK Investigational Site | Kansas City | Missouri | 64114 | — |
| GSK Investigational Site | St Louis | Missouri | 63141 | — |
| GSK Investigational Site | Alliance | Nebraska | 69301 | — |
| GSK Investigational Site | North Platte | Nebraska | 69101 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89104 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87108 | — |
| GSK Investigational Site | Hickory | North Carolina | 28601 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27609 | — |
| GSK Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| GSK Investigational Site | Bismarck | North Dakota | 58501 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| GSK Investigational Site | Grove City | Pennsylvania | 16127 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15241 | — |
| GSK Investigational Site | Bristol | Tennessee | 37620 | — |
| GSK Investigational Site | Knoxville | Tennessee | 37920 | — |
| GSK Investigational Site | Houston | Texas | 77024 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84109 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84121 | — |
| GSK Investigational Site | West Jordan | Utah | 84088 | — |
| GSK Investigational Site | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00346073, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2018 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00346073 live on ClinicalTrials.gov.